Micro-Cancers in the Thyroid: When Autoimmunity Becomes Somatic Evolution
> Paper: *Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity* > Authors: Pantelis A. Nicola, Andrew R. J. Lawson, Iñigo Martincorena, et al. > Institutions: Wellcome Sanger Institute, University of Cambridge, University of Edinburgh, and others > Published: Nature, April 14, 2026 > DOI: 10.1038/s41586-026-10493-9
A Long-Ignored Hypothesis
How do autoimmune diseases arise? The textbook answer: the immune system mistakes self tissue for an enemy and attacks. But more than sixty years ago, immunologist Frank Macfarlane Burnet proposed a more radical idea—perhaps the problem lies not in immune "recognition," but in somatic mutations in lymphocytes.
Burnet suggested that self-reactive lymphocytes that should have been eliminated might escape checkpoint surveillance by acquiring somatic mutations. The hypothesis was never verified because the technical challenge was enormous: finding the rare mutated lymphocytes among vast numbers of normal cells.
That hypothesis has now been confirmed.
What Was Found: A Mutinous Army in the Thyroid
Using the ultra-accurate single-molecule DNA sequencing technology NanoSeq, the team deeply scanned thyroid tissue from patients with Hashimoto's thyroiditis and Graves' disease.
They found hundreds to thousands of independent B-cell clones, each carrying distinct somatic mutations, all doing the same thing—disabling immune checkpoint genes.
Convergent Evolution: Different Paths, Same Destination
The most striking finding is "convergent evolution." These B-cell clones independently acquired mutations targeting the same set of genes:
| Target gene | Alias | Function | Mutation type | |---|---|---|---| | TNFRSF14 | HVEM | Key checkpoint inhibiting T-cell activation | Loss-of-function | | CD274 | PD-L1 | Sends "don't attack" signals to T cells | Loss-of-function |
TNFRSF14 mutations were especially widespread. In some biopsy samples, the team detected dozens to hundreds of independent TNFRSF14-mutant clones. Each clone represents only a small fraction of total cells (usually <1%), but together the mutant clones account for a substantial proportion of B cells.
Even more striking, some clones carried biallelic loss—both copies of a checkpoint gene were disabled—and some accumulated 4-6 driver mutations, advancing step by step like cancer cells.
Not an Immune System Gone Rogue, But "Micro-Cancers"
The paper's core argument: autoimmune disease is not simply immune overreaction, but the product of somatic evolution occurring locally in tissue.
How does cancer arise? A cell acquires mutations, escapes growth control, and proliferates into a clone. The clone accumulates further mutations, gains competitive advantages, and eventually forms a tumor.
Autoimmune disease? A B cell acquires checkpoint mutations, escapes tolerance control, forms a positive feedback loop with self-reactive T cells, proliferates into clones, and becomes progressively better at attacking self tissue.
Both are Darwinian evolution replayed locally in the body. The only difference:
- Cancer: clones aim for unlimited proliferation
- Autoimmunity: clones aim to attack self tissue
- Whole-exome sequencing: identifying candidate driver mutations
- Laser microdissection: spatially localizing mutated cells
- Methylation sequencing: confirming the identity of mutated cells
- Spatial transcriptomics: mapping mutant cells in tissue
- Single-nucleus DNA sequencing: confirming clonal independence
- Antibody synthesis: validating the self-reactivity of clones
- Different autoimmune diseases may share common mutational lineages
- Disease progression may result from clonal competition (like cancer evolutionary trees)
- Therapeutic targets may shift from "suppressing the entire immune system" to "clearing specific mutant clones"
- Develop therapies targeting checkpoint-mutant clones (analogous to targeted cancer therapy)
- Note: immune checkpoint inhibitors would add fuel to the fire, since autoimmunity here is checkpoint failure
- More likely: restore checkpoint function—e.g., gene therapy supplementing PD-L1, or cell therapies clearing mutant B cells
- Some cancer patients develop autoimmune side effects after immune checkpoint inhibitor therapy
- Certain autoimmune diseases raise or lower cancer risk
- Original paper: https://www.nature.com/articles/s41586-026-10493-9
- Companion commentary: https://www.nature.com/articles/d41586-026-01415-w
- Burnet, F. M. *The Clonal Selection Theory of Acquired Immunity* (1959)
Co-author and cancer genomicist Iñigo Martincorena is known for his work on early mutations in cancer. This time, the team turned the cancer-research lens on autoimmunity—and found both share the same underlying logic.
The Technical Breakthrough: NanoSeq
Why did it take so long to verify Burnet's hypothesis? Because detection was so hard.
Traditional bulk sequencing can only detect clones present at >5% frequency. But immune B-cell clones are extremely diverse, each representing a tiny fraction of total cells. You need to detect mutations below 1% frequency.
NanoSeq is an ultra-accurate single-molecule sequencing protocol capable of detecting mutations in individual DNA molecules with very high accuracy. The team combined it with:
The cross-validation across techniques shows these mutations are not sequencing noise—they are real, functionally important, located in B cells, and self-reactive.
What It Means
Reshaping Disease Understanding
Autoimmune disease may be redefined as "benign cancer"—not unlimited proliferation, but cells that acquired the ability to escape immune control.
This means:
Implications for Treatment
Current autoimmune treatments (glucocorticoids, immunosuppressants) are carpet bombing—suppressing the whole immune system at the cost of infection risk and serious side effects.
If disease is driven by specific mutant clones, one could theoretically:
Explaining the Cancer-Autoimmunity Link
Clinically, autoimmune diseases and cancer have long shown connections:
This study offers a unifying framework: both are products of somatic mutations escaping immune control, differing only in which cell types the mutations occur in and the resulting phenotype.
Limitations and Open Questions
The paper leaves open mysteries:
1. Mutation source: Do these somatic mutations arise from AID (activation-induced cytidine deaminase) during normal B-cell activation, or from environmental acceleration? 2. Initial trigger: Why does the thyroid first harbor mutant clones—tissue-specific properties, or simply random B-cell trafficking? 3. T-cell role: The paper focuses on B cells, but do T cells carry similar mutations? TNFRSF14 is a B–T cell interaction checkpoint, so T-cell-side mutations may matter too. 4. Other autoimmune diseases: Does a similar pattern hold in multiple sclerosis, rheumatoid arthritis, or type 1 diabetes? 5. Therapeutic feasibility: How can mutant clones be specifically eliminated without destroying normal immune function?
One-Sentence Takeaway
Autoimmune disease may not be the immune system "going mad," but thousands of micro-cancers playing out in the body—each a B-cell clone that has slipped its immune brakes. This shift in perspective may redefine how we view and treat these diseases.